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Evidence for compromised aldosterone synthase enzyme activ-
ity in preeclampsia.
Background. In normal pregnancy, an increased aldosterone
(Aldo) concentration coincides with volume expansion. In
preeclampsia, Aldo levels are low despite intravascular volume
depletion. The present investigation aimed to characterize the
compromised Aldo synthesis in preeclampsia, and to identify
the molecular basis hereof.
Methods. We recruited 66 pregnant women (24 uneventful,
42 preeclamptic). Genomic DNA was isolated from periph-
eral blood leukocytes. Urine samples were obtained for gas
chromatography-mass spectroscopic measurements of steroid
hormones reflecting apparent Aldo synthase (CYP11B2) and
11-hydroxylase (CYP11B1) activities. Polymerase chain reac-
tion (PCR)-based screening for CYP11B2 mutations was per-
formed by SSCP, restriction analysis, and sequencing.
Results. CYP11B1 activity was unaltered, but reduction of
mean tetrahydro (TH)-Aldo excretion by a factor of 3.9 indi-
cated a diminished CYP11B2 activity in preeclampsia. Accord-
ingly, the ratios of (TH-11-dehydrocorticosterone [A]+TH-
corticosterone [B]+5a-THB) to (TH-cortisone +TH-cortisol
[F]+5a-THF) and of 18-OH-THA to THAldo were increased
in preeclampsia 2.6- and 15.2-fold, respectively, indicating re-
duced Aldo synthesis due to diminished methyl oxidase (MO)
activity. A lower percentage of women with normal pregnan-
cies had CYP11B2 mutations when compared to preeclamptic
women (P < 0.05). Eight polymorphisms were detected, two of
which were non–amino acid conserving. Of those, the mutation
V386A, earlier found to jeopardize MO activity, was exclusively
observed in preeclampsia (0% vs. 17%; P < 0.05).
Conclusion. Aldo deficiency due to a compromised MO step
of Aldo synthesis favors extracellular volume depletion, and
may account for an increased risk of placental hypoperfusion
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and consecutive development of preeclampsia. The sole pres-
ence of mutation V386A in preeclamptic mothers may identify a
subgroup with an increased risk to develop preeclampsia during
pregnancy.
Hypertension in pregnancy in its most severe form,
preeclampsia, remains a major health threat complicating
pregnancies [1]. Despite considerable progress in con-
trolling the peripartal course, long-term morbidity still
affects mothers and children [2, 3]. The pathophysiology
of preeclampsia is still debated, and numerous theories
have been postulated to explain the various manifesta-
tions of this hypertensive disorder [4, 5].
Normal pregnancy is characterized by marked expan-
sion of the extracellular volume and the plasma volume,
associated with changes in renal hemodynamics, as well
as in the circulating level of several corticoids [6], likely
to adapt maternal circulation to the blood and substrate
requirements of the placenta. Among these is a marked
increase in circulating aldosterone [7–12]. Despite high
levels, the concentrations change appropriately when
gravidas are challenged with maneuvers such as salt re-
striction or loading and diuretic administration, suggest-
ing that aldosterone is a key hormone in the maintenance
of this expanded volume [13].
Plasma volume, the renin-angiotensin II system, and
the circulating aldosterone concentrations are substan-
tially lower in women with preeclampsia. Two main in-
terpretations exists to this phenomenon: the first is based
on an abnormal shifting of fluid from the vascular to the
extravascular compartment with an inappropriate sens-
ing of vascular “overfilling.” In contrast, the current study
is based on the assumption that the gestational increase
in plasma volume is a compensatory adaptation to sup-
port placental perfusion and fetal substrate delivery, and
that this adaptation is jeopardized in preeclampsia by
a vascular “underfilling” due to a reduced Aldo secre-
tion, which fails to counterbalance the fluid deficiency [8,
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Fig. 1. Enzymatic pathway of 11-hydroxylase (CYP11B1) and aldos-
terone synthase (CYP11B2). Steroid metabolites determined to assess
the metabolic pathway are depicted on the right. 11-deoxycortico-
sterone (DOC), tetrahydro-11-deoxycorticosterone (THDOC),
tetrahydro-corticosterone (THB), tetrahydro-11-dehydrocortico-
sterone (THA), 18-OH-tetrahydro-11-dehydrocorticosterone (18-OH-
THA), tetrahydro-aldosterone (THAldo).
9, 14]. According to this theory, the reduced circulating
volume limits placental blood supply directing counter-
regulatory mechanisms, which then lead to an elevated
maternal blood pressure [5].
A better understanding of Aldo synthesis originated
from cloning the Aldo-synthesizing enzyme (CYP11B2)
from adrenal zona glomerulosa [15–17]. The human
CYP11B2 is 93% homologous to the 11b-hydroxylase
(CYP11B1), an enzyme essential for cortisol synthesis.
The genes for both enzymes are closely linked on chro-
mosome 8, and are considered to arise from the dupli-
cation of a common ancestral gene [18–20]. CYP11B2
possesses 11b- and 18b-hydroxylase, as well as 18-methyl
oxidase (MO) activity. This enzymatic step is considered
rate limiting for Aldo synthesis (Fig. 1) [21]. Studies in
pregnant rats revealed an increased gestational expres-
sion of CYP11B2, even enhanced by low-salt diet [21–23].
We hypothesized that a reduced activity of the
CYP11B2 is associated with preeclampsia, and that ge-
netic variation of CYP11B2 accounts for the reduced ac-
tivity in women with preeclampsia.
METHODS
Patients
Sixty-six pregnant women, 24 with normal pregnan-
cies and 42 with preeclampsia, were recruited from the
Women’s Hospitals of the University of Berne, Switzer-
land, and from the University of Erlangen-Nuremberg,
Germany. Approval by the appropriate hospital ethics
review committee and informed consent from all women
were obtained. Basic demographic data, including blood
pressure, information on concurrent diseases, and the
present medication were obtained. Preeclamptic indi-
viduals with preexisting arterial hypertension, diabetes
Table 1. Patients characteristics
Type of pregnancy Normal pregnancy Preeclampsia P < value
N 24 42
Age years 31.4 ± 1.2 31.6 ± 0.6 NS
BMI kg/m2 27.0 ± 0.8 29.8 ± 1.0 NS
Primiparous women % 53 51 NS
Hypertension prior to
pregnancy %
0 0 NS
Delivery week 37.7 ± 0.9 32.4 ± 0.6 0.001
Birth weight g 3353 ± 168 1747 ± 114 0.001
Proteinuria g/d ND 2.8 ± 0.6 0.001
Systolic blood pressure
mm Hg
114 ± 3 161 ± 2 0.001
Diastolic blood
pressure mm Hg
71 ± 2 97 ± 1 0.001
ND, not detectable; NS, not significant.
mellitus, or renal disease were excluded from the study.
Patients were included if blood pressure was above
140/90 mm Hg and proteinuria >0.3 g/day in the absence
of urinary tract infection beyond the 20th week of gesta-
tion [24] (Table 1).
Collection of urine and blood samples and isolation of
genomic DNA
Twenty-four–hour urine samples were started for all
women at initial presentation. Urine samples of women
with normal pregnancies were matched for gestational
age; however, analysis was postponed until delivery
to verify an uncomplicated pregnancy. Urine from 20
healthy, female, nonpregnant volunteers aged 20 to 40
served as control. Ten mL blood samples were drawn
into tubes containing Na-EDTA, mixed, and stored at
4◦C. Genomic DNA was extracted from peripheral blood
leukocytes following the protocol supplied by the nucleon
BACC3 kit (Bioscience; Piscataway, NJ, USA). Purified
DNA was stored in H2O at −20◦C.
Gas chromatography-mass spectrometry (GC-MS) of
progesterone metabolites
Urinary steroid metabolites were analyzed by GC-
MS according to the method described by Shackleton
[25], which was extended to determine 11-deoxycorti-
costerone (DOC), using specifically designed programs
for selective ion monitoring.
Sample preparation consisted of pre-extraction, en-
zymatic hydrolysis, extraction from the hydrolysis mix-
ture, derivatization, and gel filtration. Medroxyproges-
terone (2.5 lg) was added as recovery standard to 1.5 mL
urine. The sample was extracted on a Sep Pak C18 col-
umn (Waters Corp., Milford, MA, USA), dried, recon-
stituted in 0.1 mol/L acetate buffer (pH 4.6), and hy-
drolyzed with powdered Helix pomatia enzyme (12.5 mg)
and 12.5 lL of b-glucuronidase/arylsulfatase liquid en-
zyme at 55◦C for 3 hours. The resulting free steroids were
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extracted on a Sep Pak C18 cartridge and a standard
mixture (5a-androstane-3a-17a-diol, stigamsterol, and
cholesteryl butyrate, 2.5 lg of each, and 0.15 lg of 3b5b-
THAldo) was added. The sample was derivatized to form
the methyloxime-trimethylsilyl ethers, and gel filtration
on a Lipidex 5000 column (Perkin Elmer Corp., Welles-
ley, MA, USA) was added. Samples were analyzed on
a Hewlett Packard gas chromatograph 6890 (Palo Alto,
CA, USA) equipped with the mass selective detector 5973
and the auto injector 7683 by selective ion monitoring
for each measured compound against a known calibra-
tion standard (3b5b-THAldo against 3a5b-THAldo and
all other steroids against stigmasterol). Ions were chosen
with respect to their retention time during a temperature-
programmed 35-minute run (210–265◦C). The ratio of
urinary steroids to urinary creatinine was calculated.
For assessment of the apparent enzyme activities,
the following ratios were derived from the steroid
measurements: the activity of 11b-hydroxylase was
from calculating of (THS/(THE+THF+5aTHF)) ×
100 and (THDOC/(THE+THF+5aTHF)) × 100. The
influence of an altered 11b-hydroxysteroid dehydro-
genase activity on the THA and THB distribu-
tion was excluded by obtaining the ratio of THB
to THA. The activity of Aldo synthase was ob-
tained by DOC/THAldo, (THDOC+DOC)/THAldo,
and (THA+THB+5aTHB)/(THE+THF+5aTHF), the
activity of Aldo synthase omitting the 18-MO conver-
sion by DOC/18-OH-THA and (THDOC+DOC)/18-
OH-THA, and the activity of the 18-MO by 18-OH-
THA/THAldo.
Screening of the genomic DNA for mutations
of CYP11B2 exon 1 to 9, including the adjacent
intronic splice sites
Polymerase chain reaction (PCR) for exon 1 through
9 of CYP11B2, including adjacent splice sites, was per-
formed following gene-specific preamplification using the
primers reported by Peter et al [26]. All reactions were
carried out with 25 pmol of each primer in a final volume
of 50 lL, containing 4 mmol/L MgCl2 buffer, 0.2 mmol/L
of each dNTP, and 1 unit of AmpliTaq Gold polymerase
(PE Biosystems, Foster City, CA, USA). The DNA was
amplified for 35 cycles with denaturation at 95◦C for
30 seconds, annealing at 60◦C for 30 seconds, and exten-
sion at 72◦C for 1 minute.
Single-strand conformation polymorphism analysis
(SSCP) gel analysis and sequencing
PCR products were initially analyzed nondenatured
and denatured (100 mmol/L NaOH, 0.25% bromophenol
blue/xylen cyanol in formamide heated 6 minutes at 95◦C)
on 12% acrylamide/piperazin-diacrylamide gels contain-
ing 7.25% glycerol using a two-buffer system. Four lL
of the PCR sample were loaded, separated at 12◦C, and
DNA was visualized by silver staining [27]. Sequence
Table 2. Mutations present in study groups
Number affected
(% affected of total)
Normal pregnancy Preeclampsia
Type of mutation (N = 24) (N = 42)
None 14 (58%) 12 (29%)a
Intron
A Intron 1-2 (1190 C/T) 2 (8%) 1 (2%)
B Intron 1-2 (1205 C/T) 7 (29%) 11 (26%)
C Intron 6-7 (5541 G/A) 3 (13%) 10 (24%)
Exon (amino acid conserved)
D Exon 3 (3309 C/T – F168F) 7 (29%) 9 (21%)
E Exon 6 (5160 A/C – R374R) 5 (21%) 4 (10%)
F Exon 7 (5609 G/A – L390L) 0 (0%) 1 (2%)
Exon (amino acid not conserved)
G Exon 3 (3323 A/G – R173K) 7 (29%) 9 (21%)
H Exon 7 (5596 T/C – V386A) 0 (0%) 7 (17%)a
Combined mutations
B+E 1 (4%) 0 (0%)
B+F 0 (0%) 1 (2%)
D+G 4 (17%) 4 (10%)
D+H 0 (0%) 2 (5%)
B+C+E 3 (13%) 3 (7%)
B+D+G 2 (8%) 3 (7%)
B+D+E+G 0 (0%) 1 (2%)
A+B+D+G 1 (4%) 1 (2%)
aP < 0.05 vs. normal pregnancy.
changes were detected by double-band shifts on the gel.
Since initial experiments indicated additional polymor-
phisms not detected by SSCP, this method was supple-
mented by restriction analysis for known mutations and
sequencing. All documented polymorphisms are summa-
rized in Table 2.
Statistical analysis
All data are presented as mean ± SEM. To test for sta-
tistically significant differences, Student t test, the Mann-
Whitney rank sum test, analysis of variance (ANOVA)
for multiple comparisons versus control group (Tukey,
Dunn), or chi-square test were used. Significance was as-
signed at P < 0.05. All statistical analyses were performed
using SYSTAT Version 10 (SPSS, Inc., Chicago, IL, USA).
RESULTS
Women investigated during normal pregnancies were
recruited from two distinct geographic regions in
Germany and Switzerland, and were verified to have an
uneventful clinical status and course of the current and
all former pregnancies. Preeclampsia was diagnosed in
the presence of proteinuria and hypertension as defined
above. These and further patient characteristics are de-
picted in Table 1. Comparable numbers of women with
either normal or preeclamptic pregnancies were primi-
parous (53% vs. 51%). Twenty percent of multiparous
women experienced a first preeclamptic episode. Anti-
hypertensive treatment in preeclampsia consisted of la-
betalol, a-methyldopa, and nifedipine, which did not alter
the urinary steroid metabolite excretion.
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Table 3. Urinary steroids
Urinary steroids/creatinine lg/mmol
I Nonpregnant II Normal III
women pregnancy Preeclampsia
(N = 20) (N = 24) (N = 36)
THE 201 ± 29a 507 ± 62b 333 ± 73
THF 103 ± 15 196 ± 62 139 ± 38
5aTHF 63.1 ± 11.3 49.4 ± 11.7 50.5 ± 9.6
DOC 0.77 ± 0.20a 2.31 ± 0.86b 5.69 ± 0.94
(THDOC+DOC) 1.5 ± 0.3a 63.5 ± 14.7 47.2 ± 12.8c
18-OH-THA 7.0 ± 2.4 13.7 ± 3.9b 34.0 ± 7.7c
THAldo 4.1 ± 0.6a 37.9 ± 12.8b 9.7 ± 1.7
THA 8.2 ± 1.3a 47.7 ± 8.1 98.3 ± 13.1c
THB 10.8 ± 2.1a 38.5 ± 8.3 67.2 ± 9.2c
5aTHB 19.8 ± 3.1 27.5 ± 3.0 44.4 ± 7.4c
aP < 0.05 I vs. II. bP < 0.05 II vs. III. cP < 0.05 I vs. III.
Hormonal data
Twenty-four–hour urine samples were obtained in
preeclamptic patients at hospital entry. In 6 of the 42
preeclamptic patients, 24-hour urine samples remained
incomplete due to urgent deliveries, and urine data were
excluded from further analysis. In the remaining patients
with preeclampsia, cesarean section or vaginal delivery
followed within 7 days. In one woman, delivery was post-
poned for 14 days. Serum creatinine was slightly increased
in preeclamptic women. The urinary THAldo excretion
was lower in preeclamptic women, almost reaching non-
pregnant levels (Table 3). Availability of the substrate for
CYP11B1 and CYP11B2, DOC, was increased in both
normal and preeclamptic pregnancies when compared to
the nonpregnant state.
Ratios indicative of CYP11B1 activity changed con-
cordantly as expected in all pregnant when compared
to nonpregnant women. Differences in 11b-dehydration
of THB to THA were absent. Steroid metabolite ra-
tios were used to determine Aldo synthase activity ac-
cording to Shackleton [25]. High ratios, as given below,
indicate low enzyme activities. Hence, a compromised
Aldo synthesis (CYP11B2) was observed in preeclamp-
tic women compared to normal pregnant women, if the
calculated ratios included the 18-MO step (Table 4):
DOC/THAldo, (THDOC+DOC)/THAldo (both re-
flecting all enzymatic steps of CYP11B2 activity; see also
Fig. 1 and Table 4), and 18-OH-THA/THAldo (reflecting
18-methyl oxidase activity), but not DOC/18-OH-THA
and (THDOC+DOC)/18-OH-THA (both reflecting the
11b- and 18b-hydroxylase activity). THAldo was low,
and its 18-OH-precursors, denoted by 18-OH-THA, were
elevated in preeclampsia when compared to normal preg-
nancies. This led to a 15.2-fold raised ratio of 18-OH-
THA to THAldo, pointing toward a metabolic defect at
the level of 18-MO activity [25] (Table 4). Analysis of in-
dividual ratios in women with preeclampsia indicated a
wide-ranging distribution (range 0.08 to 69.47), exceed-
ing the span of women with normal pregnancy in 72%
Table 4. Steroid ratios
Calculated ratios
I Nonpregnant II Normal III
women pregnancy Preeclampsia
(N = 20) (N = 24) (N = 36)
11b-hydroxylase activity
(THS/(THE+THF+
5aTHF))×100
1.12 ± 0.12a 7.50 ± 1.52 3.97 ± 0.43c
(THDOC/(THE+THF+
5aTHF))×100
0.2 ± 0.1a 12.8 ± 4.3 16.2 ± 6.0c
11b-hydroxysteroid dehydrogenase activity
THB/THA 1.30 ± 0.10 0.94 ± 0.17 0.98 ± 0.18c
Aldosterone synthase activity
DOC/18-OH-THA 0.27 ± 0.07a 1.01 ± 0.55 0.78 ± 0.23
(THDOC+DOC)/
18-OH-THA
0.5 ± 0.1a 17.2 ± 6.3 3.5 ± 0.8c
(THA+THB+5aTHB)/
(THE+THF+5aTHF)
0.11 ± 0.01a 0.28 ± 0.04b 0.74 ± 0.16c
DOC/THAldo 0.23 ± 0.07 0.15 ± 0.07b 0.95 ± 0.16c
(THDOC+DOC)/
THAldo
0.44 ± 0.07a 4.04 ± 1.06b 8.77 ± 2.83c
18-OH-THA/THAldo 2.26 ± 0.51a 0.45 ± 0.09b 6.86 ± 1.87c
aP < 0.05 I vs. II. bP < 0.05 II vs. III. cP < 0.05 I vs. III.
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Fig. 2. Methyl oxidase activity of aldosterone synthase as assessed
by the ratio of 18-OH-THA to THAldo was measured via gas
chromatography-mass spectrometry. Samples were from nonpregnant
age-matched women (N = 20), normal pregnancy (N = 24), and
preeclamptic pregnancies (N = 36). Individual values and mean ± SEM
(box) are given. ∗P < 0.05 nonpregnant vs. normal pregnant women;
∗∗P < 0.05 normal pregnant vs. preeclamptic women; ∗∗∗P < 0.05 non-
pregnant vs. preeclamptic women.
(Fig. 2). No correlation was found with age, gestational
week, number of pregnancies, and history of hypertensive
diseases in earlier pregnancies.
Genetic analysis of the CYP11B2 gene
The analysis was performed by CYP11B2-specific
preamplification and PCR of all individual exons with
adjacent intron sites to enable detection of splice site
variations. Analysis by SSCP did not allow the identifica-
tion of all mutations present in the women investigated
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Fig. 3. SSCP analysis detected the amino acid changing mutations
R173K and V386A of exons 3 and 7, respectively, but not the amino
acid conserving polymorphism R374R of exon 6. Known mutations
were additionally identified by suitable restriction analysis. Sequenc-
ing of exons 1 to 9, including the adjacent intron-exon boundaries, was
applied to identify further mutations of CYP11B2.
(Fig. 3). Consequently, restriction analysis was applied to
known mutations in the presence of suitable restriction
sites, and the PCR products were sequenced. Mutations
were absent in 58% of the women with normal pregnan-
cies, but only in 29% of preeclamptic women (P < 0.05).
Two of the three different intronic polymorphisms iden-
tified in both groups of patients (mutation A and B in
Table 2) have not been described before. Mutation C,
which was more abundant in preeclampsia, is situated at
a branch site involved in intron-exon splicing. Faulty splic-
ing by this mutation was excluded in cell culture (data not
shown). Three of the five different exon mutations were
identified in both groups, among them all of the three
amino acid conserving ones (Table 2). Polymorphism H,
the known V386A mutation, was exclusively detected in
17% of preeclamptic women in this limited group of pa-
tients (P < 0.05 vs. normal pregnancy). Combinations of
intron and exon mutations occurred (Table 2, Fig. 4).
DISCUSSION
High Aldo levels and the increased circulating plasma
volume found in normal pregnancies may represent a
physiologic adaptation to support placental perfusion
and fetal substrate delivery [7–13]. In preeclampsia, pro-
nounced edema formation is observed in the presence
of intravascular volume depletion. Salt restriction and
the prescription of loop diuretics do not prevent or im-
prove the course of preeclampsia, but rather enhance
the risk for complications in humans [28, 29]. This ob-
servation in humans is in line with studies in pregnant
rats [21]. In these animals, sodium deprivation led to a
greater increase in Aldo production and expression of
Aldo synthase transcripts than in nonpregnant rats, sug-
gesting that this enzyme system is sensitized in pregnancy
Intron
Exon
A B D G E C H F
5'-UTR
1 2 3 4 5 6 78 9
3'-UTR
Fig. 4. Scheme of all detected mutations of CYP11B2. Numbering is
as in Table 2.
to accommodate gestational volume homeostasis. Thus,
one might predict that a compromised Aldo synthesis
would abrogate the pregnancy-associated expansion of
the circulating fluid volume. Consecutively, the intravas-
cular volume depletion would reduce placental perfu-
sion with subsequent placental ischemia and a systemic
maternal hypertensive response, leading to the clinical
phenotype of preeclampsia [5]. The hypothesis that re-
duced Aldo synthesis accounts for preeclampsia at least
in some patients is supported by a repeatedly reported di-
minished Aldo production in preeclampsia [8, 9, 14]. This
observation is confirmed in the present investigation by
measuring THAldo, a sensitive parameter to follow Aldo
release [30]. So far, it is unknown whether these reduced
Aldo secretion rates are the cause or the consequence of
preeclampsia. Therefore, insight into the enzymatic steps
and into the genetics of the enzymes accounting for Aldo
synthesis might provide a clue to the relevance of reduced
Aldo synthesis for the pathogenesis of preeclampsia.
The Aldo synthase enzyme comprises 11b-
hydroxylase, 18b-hydroxylase, and 18-MO activities
(Fig. 1). The most appropriate reference method to mea-
sure steroid hormones, GC-MS, was applied, as has been
suggested before [25, 31, 32]. All steroid metabolites
were corrected for urinary creatinine concentrations to
exclude sampling inaccuracies. A compromised Aldo
synthesis was evidenced by elevated ratios of corticos-
terone to cortisol metabolites ([THA+THB+5aTHB]/
(THE+THF+5aTHF]), and of total DOC to THAldo
[25]. Detailed analysis of urinary metabolites indicated a
reduced methyl oxidation of 18-hydroxysteroids to Aldo
in the majority of preeclamptic women, a contention
supported by elevated 18-OH-THA and decreased
THAldo concentrations, as well as by an increased
ratio of 18-OH-THA to THAldo in the majority of our
preeclamptic patients [25]. Previous and the current data
suggest that in normal pregnancy Aldo increases more
than do its 18-hydroxysteroid precursors, resulting in a
diminished ratio of 18-OH-THA to THAldo, when com-
pared to the nonpregnant state [12, 25]. In preeclampsia,
this ratio rises even compared to nonpregnant women
(Fig. 2, Table 4), suggesting a missing adaptation of the
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Aldo synthesis to pregnancy at the level of 18-methyl
oxidation.
The steroid profile derived by us did not indicate a
sufficient compensatory role of steroids with mineralo-
corticoid transactivation potential, such as DOC and sub-
stance B, to substitute for the missing Aldo release of
preeclamptic pregnancies (Table 3). DOC and substance
B do have transactivation properties for the human min-
eralocorticoid receptor, but they are less effective. Maxi-
mal transactivation of the mineralocorticoid receptor by
these steroids even at concentrations 101 to 102 times
above those of Aldo is expected not to exceed 40% to
70% of that of Aldo [33, 34]. Additionally, DOC concen-
trations were found to be unresponsive to variations in
sodium loading in normal pregnancies in previous studies
[11, 35].
Based on the altered urinary steroid profile we
postulated a loss-of-function mutation of the Aldo-
synthesizing gene CYP11B2. The analysis revealed multi-
ple polymorphisms in the exons and the adjacent intronic
sites (Fig. 3, Table 2). The new intronic polymorphisms A
and B were not increased in preeclampsia. In contrast, the
intron polymorphism C, which has been described earlier
[36], was slightly more frequent in women with than with-
out preeclampsia (Table 2). This mutation is within the
branch region close to exon 7. In vitro splicing performed
by us to assess its functional relevance yielded negative
results (data not shown) [37]. This suggested, but did not
finally prove, this mutation to be irrelevant in vivo.
All 5 exon mutations present in our population have
been described previously (Fig. 3, Table 2) [38–40]. Two of
those, R173K and V386A, were amino acid changing. The
polymorphism R173K, which we observed slightly less
frequently in patients with preeclampsia (Table 2), has
been associated with low renin hypertension in Chilean
residents [39]. In another study, mutation R173K was
not related to blood pressure, and occurred in 14% of
a French nonhypertensive population [41].
In the present study, mutation V386A solely appeared
in preeclamptic women, significantly different from nor-
mal pregnancies (Table 2). A center bias toward an in-
creased incidence of the described mutation is possible
because the rate of recurrent preeclampsia was high in
our study population, and metabolic disease states as
a cause of recurrent preeclampsia were excluded. In
France, this mutation showed up in 4% of a small con-
trol group, and in 18% of patients with essential hyper-
tension, a disease closely associated with preeclampsia.
The mutation V386A has also been described in patients
with corticosterone methyl oxidase type II (CMO-II) de-
ficiency [38, 41–43]. In vitro transfection studies suggested
a slightly reduced activity of this mutant [38, 41]. Yet in
vitro assays of Aldo synthase may only incompletely rep-
resent the in vivo situation because low efficiency con-
version over a prolonged period in vitro could allow for a
substantial conversion of the substrate, but may be inad-
equate for efficient in time conversion in vivo [41]. Ad-
ditional regulatory factors may also be involved. V386A
represents the sequence normally present in CYP11B1,
which is highly homologous to CYP11B2, and thus, its
occurrence has been speculated to be an ancestral gene
conversion rather than an independent mutation [38].
Variably, combined with other mutations that do not al-
ter Aldo synthase activity significantly themselves, the
polymorphism V386A further reduced CYP11B2 activity
[41]. Pascoe et al [38] quoted that mild CMO-II deficien-
cies may be rather frequent, exacerbated by sodium de-
privation. Thus, it is conceivable that pregnancy due to its
increased demand for Aldo discloses mild CMO deficien-
cies. The exclusive presence of V386A in patients with
preeclampsia suggests that carriers of this mutation may
share an increased risk to develop preeclampsia, yet this
subgroup must be elucidated in further large-scale stud-
ies, and cannot be used to predict preeclampsia at present.
In addition to genetic factors, humoral factors may com-
promise aldosterone synthesis. Earlier cell culture studies
suggested a down-regulation of aldosterone production
by proinflammatory cytokines, including TNF-a and in-
terleukins, which are also released and elevated in the
peripheral circulation of women with preeclampsia [44,
45]. Adult human adrenal cells respond differentially to
cytokine exposure in the presence or absence of different
primary stimulators of Aldo release, such as angiotensin
II [46], further complicating a clinical evaluation.
CONCLUSION
The present investigation revealed a reduced appar-
ent activity of the MO component of the Aldo synthase,
leading to a reduced Aldo secretion rate in a substan-
tial fraction of women with preeclampsia. The decreased
Aldo synthase activity is unlikely to be explained by mu-
tations alone, and future work will explore regulatory
mechanisms related to this enzyme’s activity, such as an
altered promotor activity, splice variations, or endoge-
nous inhibitors. Due to the potential preventive and ther-
apeutic consequences, such as sodium supplementation,
further studies are mandatory.
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